Stocks · News reference
8-K filing — CDT Equity Inc. (CDTTW)
Filed: 2026-09-25 AccNo: 0001493152-26-044248 Size: 306 KB Item 3.03: Material Modifications to Rights of Security Holders Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- edgar
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
CDT Provides Capital Update and Confirms No Nasdaq Deficiencies
CDT Equity Inc. (Nasdaq: CDT) announced 13.7 million shares outstanding as of August 31, 2026, with a market capitalization of approximately $23.0 million. The company confirmed it no longer has outstanding deficiencies with Nasdaq following recent share issuances and corporate actions. CDT, a data-driven biopharmaceutical development company, reported stockholders' equity of approximately $103 million as of June 30, 2026.
CDT Validates Enhanced Solid-Form Properties Within Its IP Portfolio
CDT Equity Inc. announced the development of new solid forms and crystal structures of its existing drug compounds with improved stability, solubility, and manufacturability. The company has filed patents for new therapeutic uses identified through AI-driven analysis, targeting underserved patient populations. CDT plans to advance these findings through laboratory models and pursue licensing partnerships, aiming to create a differentiated, patent-protected portfolio with reduced scientific risk.